Loading...
XASE
IBIO
Market cap11mUSD
Jul 31, Last price  
0.68USD
1D
-0.29%
1Q
-32.67%
Jan 2017
-99.66%
IPO
-99.96%
Name

Ibio Inc

Chart & Performance

D1W1MN
P/E
—
P/S
49.02
EPS
—
Div Yield, %
—
Shrs. gr., 5y
151.79%
Rev. gr., 5y
-35.52%
Revenues
225k
896,273987,0581,176,6040520,0801,277,3451,007,000205,0001,851,000948,000394,000444,0002,018,0001,638,0002,371,0002,383,0000225,000
Net income
-25m
L-15.03%
-1,666,034-1,869,295-1,907,296-6,078,020-12,142,451-5,675,838-6,198,000-3,666,000-6,625,000-9,764,000-14,532,000-16,105,000-17,593,000-18,915,000-23,259,000-51,005,000-29,311,000-24,907,000
CFO
-19m
L-39.04%
-849,378-1,149,451-2,024,807-2,348,223-5,338,188-6,009,646-4,849,000-4,116,000-4,725,000-8,072,000-13,163,000-13,480,000-13,975,000-13,345,000-30,064,000-37,480,000-30,436,000-18,554,000
Earnings
Sep 18, 2025

Profile

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
URL
https://www.ibioinc.com/
IPO date
Aug 18, 2008
Employees
105
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
225
 
Cost of revenue
16,859
30,449
Unusual Expense (Income)
NOPBT
(16,634)
(30,449)
NOPBT Margin
Operating Taxes
(1,639)
Tax Rate
NOPAT
(16,634)
(28,810)
Net income
(24,907)
-15.03%
(29,311)
-42.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
25,516
11,448
BB yield
Debt
Debt current
953
13,598
Long-term debt
6,983
7,613
Deferred revenue
Other long-term liabilities
63
768
Net debt
(6,274)
14,951
Cash flow
Cash from operating activities
(18,554)
(30,436)
CAPEX
(210)
(5,738)
Cash from investing activities
906
7,009
Cash from financing activities
24,494
2,301
FCF
15,683
(23,954)
Balance
Cash
14,210
4,301
Long term investments
1,959
Excess cash
14,199
6,260
Stockholders' equity
(313,838)
(288,920)
Invested Capital
339,685
317,949
ROIC
ROCE
EV
Common stock shares outstanding
3,831
612
Price
Market cap
EV
EBITDA
(15,384)
(29,069)
EV/EBITDA
Interest
172
Interest/NOPBT